THE CHRIST HOSPITAL LINDNER RESEARCH & WOMEN'S HEART CENTER

WARRIOR

WOMEN'S ISCHEMIA TRIAL TO REDUCE EVENTS IN NON-OBSTRUCTIVE CORONARY ARTERY DISEASE (CAD)

STUDY OVERVIEW:

- The proposed WARRIOR (Women's Ischemia Trial to Reduce Events In Non-Obstructive CAD) trial is a multicenter, prospective, randomized, blinded outcome evaluation (PROBE design) evaluating IMT (intensive medical therapy) vs. UC (Usual Care) in 4,422 symptomatic women with ischemia but no obstructive CAD. The hypothesis is that IMT will reduce major adverse cardiovascular events (MACE) by 20% vs UC. The primary outcomes are first occurrence of death, MI, Stroke/TIA, Hospitalization for chest pain or heart failure. Secondary outcomes include quality of life, health resource consumption, angina, CV death and primary outcome components. Follow-up will be 3- years using 50 sites.

ELIGIBILITY:

- Women with angina or equivalent symptoms of sufficient severity to seek, or have sought, referral for coronary angiography or coronary CT angiogram (CCTA) within the previous 5 years.

INCLUSION CRITERIA:

- Signs and symptoms of suspected ischemia prompting referral for further evaluation by cardiac catheterization or coronary CT angiogram last 5 years.
- Willing to provide written informed consent.
- Age ≥18 yrs.
- Non-obstructive CAD defined as <50% diameter reduction of a major epicardial vessel on invasive angiography or a CCTA.

EXCLUSION CRITERIA:

- History of noncompliance (with medical therapy, protocol, or follow-up).
- History of non-ischemic dilated or hypertrophic cardiomyopathy.
- Documented ACS within previous 30 days.
- LVEF <40%, NYHA HF class III-IV, or hospitalization for HFrEF within 180 days.
- Stroke within previous 180 days or intracranial hemorrhage at any time.
- End-stage renal disease, on dialysis, or estimated glomerular filtration rate (eGFR) <30 ml/min.
- Severe valvular disease or likely to require surgery/TAVR within 5 yrs.
- Life expectancy <3-yrs. due to non-cardiovascular comorbidity.
- Enrolled in a competing clinical trial.
- Prior intolerance to both an ACE-I and ARB.
- Pregnancy (all pre-menopausal females must be negative serum pregnancy test).

***You will receive study medication free of charge if randomized to the IMT arm

For more information, please contact the Lindner Research Center at: 513-585-1777
To learn more, please visit: TheChristHospital.com/womens-heart